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Backgrounds: Inhaled corticosteroids (ICS)/inhaled long-acting beta2-agonists (LABA)
combination drugs are widely used for the long-term management of chronic obstructive
pulmonary disease (COPD). However, COPD is a heterogeneous condition and treatment
with ICS is associated with a higher risk of pneumonia. The identiﬁcation of a speciﬁc
markerforpredictingtheefﬁcacyofICS/LABAonpulmonaryfunctionwouldbeusefulinthe
treatment of COPD. Methods: Fourteen COPD patients receiving tiotropium therapy par-
ticipated consecutively.The relationship between the baseline exhaled nitric oxide (FENO)
levels as well as serum markers and changes in pulmonary function by ﬂuticasone propi-
onate (FP)/salmeterol (SAL) were analyzed. Results:FP/SAL therapy signiﬁcantly improved
forced vital capacity, forced expiratory volume in 1s (FEV1), and the third phase slope of
the single nitrogen washout curve ( N2) as well as the FENO level.The baseline FENO lev-
els and positive speciﬁc IgE (atopy+) were signiﬁcantly associated with airway obstructive
changesassessedbyFEV1 and N2.AbaselineFENO level>35ppbyielded80.0%sensitiv-
ity and 66.7% speciﬁcity for identifying the subjects with signiﬁcant improvement in FEV1
(greater than 200mL). An atopy+ yielded 60.0% sensitivity and 88.9% speciﬁcity for an
improvement in FEV1. When combined with FENO >35ppb and atopy+, it showed 40%
sensitivity and 100.0% speciﬁcity for FEV1 improvement. Alternatively, COPD subjects
with FENO ≤35ppb and atopy− did not show signiﬁcant improvement in FEV1. Conclu-
sion: Combining FENO and speciﬁc IgE may be a useful marker for predicting the response
to ICS/LABA on airﬂow limitation in COPD.
Keywords: airﬂow limitation, airway inﬂammation, atopy, exhaled nitric oxide, inhaled corticosteroid, inhaled
long-acting beta2-agonist
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a chronic
pulmonary inﬂammatory disorder, and pathological changes
are observed in the proximal airways, peripheral airways, lung
parenchyma, and pulmonary vasculature. These inﬂammatory
and structural changes lead to various physiological changes
in lung function, including airﬂow limitation, air trapping,
ventilation heterogeneity, and gas exchange abnormalities (Rabe
et al.,2007).
In the long-term management of stable COPD, long-acting
bronchodilators are central to the pharmacologic treatment (Celli
and MacNee, 2004; Rabe et al., 2007). The use of inhaled cor-
ticosteroids (ICS) is recommended to reduce the frequency of
exacerbations in symptomatic patients with a forced expiratory
volume in 1s (FEV1) of less than 50% of predicted and repeated
exacerbations (Mahler et al., 2002; Calverley et al., 2003; Jones
etal.,2003;Szafranskietal.,2003;Spenceretal.,2004).Todate,the
Abbreviations: FENO, exhaled nitric oxide fraction; FP, ﬂuticasone propionate;
ICS, inhaled corticosteroid; LABA, inhaled long-acting beta2-agonist; ppb, parts
per billion; SAL, salmeterol.
effectivenessof ICSforpatientswithCOPDremainscontroversial
(Pauwels et al., 1999; Vestbo et al., 1999; Burge et al., 2000; Lung
Health Study Research Group, 2000). Recently, ICS/inhaled long-
acting beta2-agonists (LABA) combination therapy has become
widelyusedinclinicalpractice,achievingprofoundimprovements
of pulmonary function, symptoms and health-related quality of
life,andpreventingexacerbationscomparedwithplacebooreither
monotherapy alone (Mahler et al., 2002; Calverley et al., 2003,
2007; Hanania et al., 2003; Szafranski et al., 2003; Wedzicha
et al., 2008). However, a meta-analysis has clariﬁed that the efﬁ-
cacy of ICS/LABA combination therapy compared with LABA
monotherapy on pulmonary function shows statistical hetero-
geneity(Rodrigoetal.,2009).Inaddition,ICStherapymayleadto
increased risk of pneumonia in the patients with COPD (Drum-
mondetal.,2008;Wedzichaetal.,2008;Rodrigoetal.,2009;Singh
et al., 2009). These ﬁndings strongly suggest that it is important
to clarify a clinical marker that has high speciﬁcity for identi-
fying COPD patients for whom ICS/LABA combination would
be beneﬁcial. Importantly, the effects of ICS in COPD are much
less dramatic than in asthma and the long-term safety of ICS in
patients with COPD is not well established.
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The aim of this study was to assess a speciﬁc marker for
predicting the efﬁcacy of ICS/LABA combination therapy for pul-
monary function. We investigated the relationship between the
baseline levels of FENO, serum markers, and changes in pul-
monary function by additive treatment of ﬂuticasone propionate
(FP)/salmeterol (SAL) combination to tiotropium.
MATERIALS AND METHODS
STUDY SUBJECTS
Fourteen stable COPD patients receiving long-acting muscarinic
receptor antagonist (tiotropium 18μg/day) were consecutively
enrolled from the outpatient clinic of Wakayama Medical Univer-
sity Hospital. COPD was diagnosed according to the guidelines of
the Global Initiative for Chronic Obstructive Lung Disease (Rabe
et al., 2007). All subjects had airﬂow limitation with FEV1 <80%
of predicted and FEV1/forced vital capacity (FVC) ratio <70%.
They had a smoking history of more than 10 pack-years and had
emphysema on high-resolution computed tomography (HRCT)
of the lungs. Current smokers were excluded because of the
inﬂuence of smoking on the exhaled nitric oxide (FENO)l e v e l s
(McSharryetal.,2005).Subjectswhohadhistoriesandsymptoms
of atopic rhinitis, chronic rhinosinusitis, atopic dermatitis, food
allergy,asthma,orotherlungdiseaseswerecarefullyexcludedfrom
thestudy.ThosewhohadanexacerbationofCOPDinthe4-weeks
preceding the study were not included. Rescue use of salbutamol
(200μgasneeded)forsymptomreliefwasallowed.Thestudysub-
jectswhohadbeenusingLABA,ICS,ICS/LABAcombination,oral
beta2-agonists,regular use of inhaled short-acting beta2-agonists,
regular use of inhaled, short-acting muscarinic receptor antag-
onists, and slow release theophylline were not allowed such use
for at least 4weeks before and during the study. The protocol
was approved by the local ethics committee and performed after
written informed consent was obtained from each subject.
STUDY DESIGN
Pulmonary function test, FENO measurement, blood sampling,
and HRCT of lungs were performed on the ﬁrst visit.After assess-
ment of the baseline values, FP/SAL (250/50μg) was added twice
daily for 12weeks, and then pulmonary function test and FENO
measurementwererepeated.Thesevariablesweremeasured2–4h
prior to the dosing of tiotropium and FP/SAL (Figure 1).
FIGURE1|S t u d ydesign.
PULMONARY FUNCTION TESTING
Forced vital capacity, FEV1, forced expiratory ﬂow (FEF), slope
of the single breath nitrogen washing curve ( N2), total lung
capacity (TLC), residual volume (RV), and diffusion lung car-
bon monoxide (DLCO) were evaluated using a dry rolling seal
spirometer (CHESTAC-8800; Chest, Inc., Tokyo, Japan).
EXHALED NO MEASUREMENT
FENO was measured in accordance with the current guidelines
(ATS/ERS, 2005) using a chemoluminescence analyzer (modiﬁed
NA-623N
®
; Chest, Inc., Tokyo, Japan). Exhalations were repeated
to obtain two acceptable values that agreed within 10% deviation,
and the average of these two values was registered. All subjects
were fasted for 1h before the measurements.
BLOOD SAMPLING
C-reactive protein (CRP), complete blood cell count, differen-
tial count of leukocytes, total serum immunoglobulin E (IgE)
levels, and speciﬁc IgE for common allergens including Der-
matophagoidespteronyssinus (DP),Dermatophagoidesfarina (DF),
house dust 1 (HD1), house dust 2 (HD2), were examined. Posi-
tive speciﬁc IgE to at least one allergen was assumed to conﬁrm a
diagnosis of atopy.
STATISTICAL ANALYSIS
Statistical analysis of changes in pulmonary function and FENO
were assessed using Wilcoxon signed-ranks test. Spearman’s rank
correlations were calculated to determine the relative changes
between physiologic parameters and continuous data (eosinophil
cell counts, total serum IgE, and FENO values). Comparison
between atopic and non-atopic subjects was made by Mann–
Whitney U-tests. The results are presented as mean±SE. A value
of p <0.05 was considered to be signiﬁcant.
RESULTS
The baseline characteristics are listed in Table 1. All subjects
were ex-smokers, and males were over-represented. The major-
ity (65%) of the study subjects was stage 2, four were stage 3
and one was stage 4. The mean FENO level was 36.4ppb, and
Table 1 | Baseline characteristics of the study subjects.
Number (female/male) 14 (2/12)
Age (years) 70.0±5.2
Body mass index (kg/m2) 22.7±1.9
Pack years (years) 52.7±8.5
GOLD classiﬁcation (stage2/stage3/stage4; n) 9/4/1
FENO (ppb) 36.4±4.7
White blood cells (/μL) 5158±274
Blood Eosinophils (/μL) 158±38
C-reactive protein (mg/Dl) 0.13±0.05
Immunoglobulin E RIST (IU/mL) 170.6±47 .5
Immunoglobulin E RAST for DP/DF/HD (n) 4/3/4
GOLD, Global Initiative for Chronic Obstructive Lung Disease; FENO, frac-
tion of exhaled nitric oxide; DP , Dermatophagoides pteronyssinus; DF , Der-
matophagoides farina; HD, house dust. All values are mean±SE.
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Table 2 | Lung function and exhaled nitric oxide before and after treatment with inhaled ﬂuticasone/salmeterol combination.
Before After Difference (range) p-value
FVC (L) 2.99±0.17 3.12±0.19 0.15 (−0.15 to 0.64) <0.05
%FVC (%) 93.0±4.2 96.1±4.9 3.1 (−5.2 to 15.9) 0.16
FEV1 (L) 1.50±0.11 1.63±0.10 0.13 (−0.11 to 0.40) <0.05
FEV1/FVC (%) 51.4±3.8 54.3±3.9 2.9 (−3.1 to 16.6) 0.16
%FEV1 (%) 57 .6±4.4 62.0±3.6 4.4 (−8.7 to 15.9) <0.05
%FEF50%FVC (%) 21.5±3.5 24.0±3.9 2.6 (−9.0 to 12.1) 0.11
%FEF75%FVC (%) 20.7±2.7 24.1±3.5 3.5 (−12.7 to 14.1) <0.05
%TLC (%) 100.1±0.3 105.8±0.3 5.7 (−6.6 to 32.9) 0.11
%RV (%) 120.1±14.7 112.8±15.2 −7. 3 ( −78.1 to 64.3) 0.55
 N2 (%) 3.07±0.36 2.44±0.24 −0.6 (−2.6 to 0.8) <0.05
%DLCO/V A (%) 64.9±7. 8 6 7. 4 ±7 .7 2.6 (−10.7 to 17 .6) 0.35
FENO (ppb) 36.4±4.7 23.9±3.6 −12.5 (−52.2 to 4.4) <0.05
FVC, forced vital capacity; FEV1, forced expiratory volume in 1s; FEF , forced expiratory ﬂow;TLC, total lung capacity; RV, residual volume;  N2, slope of the single
breath nitrogen washing curve; DLCO, diffusion lung carbon monoxide; VA, alveolar volume; FENO, fraction of exhaled nitric oxide. All values are mean±SE.
FIGURE 2 | Correlation between baseline levels of FENO and
FP/SAL-mediated changes in FEV1 (A) and slope of the single breath
nitrogen washing curve [ N2 (B)].The lines correspond to the ﬁtted
regression of the equation. Baseline  N2 values/ N2 values after FP/SAL
combination treatment was deﬁned as  N2 ratio.
four subjects were deﬁned as having atopy. The mean FENO levels
were similar between the subjects with or without atopy (atopy+,
43.6ppb;atopy−,33.5ppb;p =0.63).Table 2 showsthelungfunc-
tion and FENO values before and 12-weeks after treatment with
FP/SAL combination therapy. The treatment with FP/SAL sig-
niﬁcantly improved FVC, FEV1, %FEV1, %FEF75%FVC, and  N2
(all p <0.05). The median change of FEV1 was 0.13L ranging
from −0.11 to 0.40L. The mean FENO level was also signiﬁcantly
reduced by the treatment with FP/SAL (p <0.05).
The baseline FENO level was not associated with the changes in
FEV1 (r =−0.16, p =0.60), but signiﬁcantly correlated with the
changes in  N2 (r =−0.69, p <0.01; Figure 2). The relationship
between the baseline FENO levels and the changes in other pul-
monaryphysiologicalparameterswerenotsigniﬁcant.Amongthe
serum markers,the subjects with positive speciﬁc IgE showed sig-
niﬁcantlyhigherimprovementinFEV1 (p <0.05),butnotin N2
(Figure 3). Other serum markers including blood eosinophils,
CRP, and total IgE levels were not correlated with the changes
in any physiological parameters.
Fromthepreviousresults,thebaselineFENO levelsandpositive
speciﬁc IgE were signiﬁcantly associated with airway obstructive
FIGURE 3 | Scatter plots of FP/SAL-mediated changes in FEV1 (A) and
slope of the single breath nitrogen washing curve [ N2 (B)] values in
the subjects with positive or negative speciﬁc IgE results.
changes assessed by FEV1 and  N2. Therefore, FENO and atopy
were selected and their sensitivity and speciﬁcity for predicting
a signiﬁcant improvement in FEV1 (greater than 200mL) were
analyzed. The rationale for selecting 35ppb as a cutoff point for
FENO was based on previously reported upper reference ranges in
FENO in the Japanese adult population (Matsunaga et al., 2010).
In our study, as shown in Table 3, 5 of 14 COPD subjects (36%)
showed a signiﬁcant improvement in FEV1 by additive FP/SAL
therapy. A baseline FENO level >35ppb yielded 80.0% sensitivity
and 66.7% speciﬁcity for identifying the subjects with signiﬁcant
improvement in FEV1, with a positive predictive value (PPV) of
57.1% and negative predictive value (NPV) of 85.7%. A positive
resultofspeciﬁcIgE(atopy+)yielded60.0%sensitivityand88.9%
speciﬁcity of an improvement in FEV1, with PPV of 75.0% and
NPVof 80.0%.WhencombinedwithFENO >35ppbandatopy+,
it showed 40% of sensitivity and 100.0% speciﬁcity,with a PPV of
100.0% and NPV of 75.0% for FEV1 improvement. Alternatively,
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COPD subjects with FENO ≤35ppb and atopy− did not show
signiﬁcantimprovementinFEV1 byadditivetreatmentof FP/SAL
combination to tiotropium (Figure 4).
DISCUSSION
This is the ﬁrst study to identify that combining FENO and spe-
ciﬁc IgE appears to be a useful marker for predicting the response
to ICS/LABA of airﬂow limitation in COPD. We demonstrated
that FVC, FEV1, and  N2 values, as well as the FENO levels,
were signiﬁcantly improved by additional treatment with FP/SAL.
The increased FENO levels at baseline and atopy+ were signiﬁ-
cantlyassociatedwithairwayobstructivechangesassessedbyFEV1
and  N2. Furthermore, COPD subjects with FENO ≤35ppb and
atopy− did not show signiﬁcant improvement in FEV1.
Use of ICS is recommended to reduce the frequency of exac-
erbations in symptomatic patients with a FEV1 of less than 50%
predicted and repeated exacerbations (Mahler et al.,2002; Calver-
ley et al., 2003; Jones et al., 2003; Szafranski et al., 2003; Spencer
et al., 2004; Rabe et al., 2007). ICS/LABA combination therapy
has obtained widespread acceptance in clinical practice. In the
largest systematic review designed to assess the safety and efﬁcacy
of the regular use of ICS/LABA compared with the use of LABA
alone in stable with moderate-to-very severe COPD, treatment
with ICS/LABA signiﬁcantly increased the risk of not only pneu-
monia, but also otopharyngeal candidiasis and viral respiratory
infections (Rodrigo et al., 2009). Furthermore, a meta-analysis
has clariﬁed that the efﬁcacy of ICS/LABA combination ther-
apy compared with LABA monotherapy on pulmonary function
showed statistical heterogeneity (Rodrigo et al., 2009). Therefore,
FIGURE 4 | Distribution of the subjects whose FEV1 was increased
greater than 12% by FP/SAL combination treatment stratiﬁed by
baseline FENO level and speciﬁc IgE results.
theidentiﬁcationof aspeciﬁcmarkerforpredictingtheefﬁcacyof
ICS/LABA would be useful in the treatment of COPD.
We showed that the FENO levels were signiﬁcantly improved by
theadditionaltreatmentwithICS/LABA.Thisﬁndingisconsistent
with those of previous studies on steroid therapy in patients with
COPD (Zietkowski et al., 2005; Kunisaki et al., 2008; Lehtimaki
etal.,2010).AmongpatientswithCOPD,ithasbeenproposedthat
steroid responsiveness is related to eosinophilic airway inﬂamma-
tion (Chanez et al., 1997). Several studies showed that the level of
sputum eosinophils can predict the response to a short course
of oral prednisolone or ICS in COPD (Pizzichini et al., 1998;
Brightlingetal.,2000,2005;Leighetal.,2006).Recently,onestudy
showed that FENO can predict the response to oral prednisolone
(Dummeretal.,2009)andthreestudiesshowedthatFENOcanpre-
dicttheresponsetoICSinCOPD(Zietkowskietal.,2005;Kunisaki
et al., 2008; Lehtimaki et al., 2010). These results suggest that
thereisasubgroupwitheosinophilicinﬂammationamongCOPD
patients, and that the detection of eosinophilic inﬂammation
could be useful for predicting the efﬁcacy of steroid therapy.
In the present study, when FENO was >35ppb, the sensitiv-
ity was 0.80 and the speciﬁcity was 0.67 for the subjects whose
FEV1 was increased greater than 12% by FP/SAL combination
treatment, although the baseline FENO was not correlated with
the changes in FEV1 after combined ICS/LABA. A relationship
betweenthebaselineFENO levelsandsteroid-mediatedchangesin
thepulmonaryphysiologicalparametershasbeenreportedinsev-
eral previous studies (Zietkowski et al.,2005;Kunisaki et al.,2008;
Dummer et al., 2009; Lehtimaki et al., 2010). The baseline FENO
was a predictor of the increase in FEV1 by steroid therapy (Dum-
mer et al.,2009),and high levels of bronchial NO ﬂux were found
to be related to symptom relief and improvement of the airway
obstructionduringtreatmentwithinhaledﬂuticasone(Lehtimaki
et al.,2010). The reason that the baseline FENO was not correlated
with the changes in FEV1 in our study may be due not only to the
effect of ICS but also that of LABA. The results of these studies
and ours suggested that the measurement of FENO may enable
theselectionof individualCOPDpatientswhocouldbeneﬁtfrom
steroid therapy.
Interestingly, the present study showed a signiﬁcant correla-
tion between positive speciﬁc IgE and the degree of improvement
in FEV1. Atopy was found to be associated with increased FENO
irrespective of asthma (Malinovschi et al., 2009) and is known
to favor eosinophilic inﬂammation (Schleich et al., 2010). This
is the ﬁrst report showing that speciﬁc IgE is a useful marker to
predict the efﬁcacy of ICS/LABA combination in COPD patients.
In contrast, the peripheral blood eosinophils and the total serum
IgE were insensitive markers for predicting the efﬁcacy, which is
compatible with previous data (Brightling et al.,2005).
Table 3 | Sensitivity, speciﬁcity, positive predictive values (PPVs), and negative predictive values (NPVs) at FENO >35ppb, atopy+, and
combined with FENO >35ppb and atopy+ for predicting FEV1 improvement greater than 200mL.
Marker Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%)
FENO >35ppb 80.0 66.7 57 .1 85.7
Atopy+ 60.0 88.9 75.0 80.0
FENO >35ppb and atopy+ 40.0 100.0 100.0 75.0
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When FENO >35ppb and/or atopy+ were combined, the sen-
sitivity was 1.0 and the speciﬁcity was 0.56 for the subjects
whose FEV1 was increased greater than 12% by FP/SAL combi-
nation treatment. This sensitivity was higher than the 0.6 when
FENO >35ppb. Combining the measurement of FENO and spe-
ciﬁc IgE may become a predictor of COPD patients who could
beneﬁtfromICS/LABAcombination.Moreimportantly,thespeci-
ﬁcity of a low (normal) FENO (≤35ppb) and atopy− was 100%,
indicating that a combining the measurement of FENO and spe-
ciﬁc IgE would help the clinicians to avoid prescribing ICS/LABA
treatment for non-responsive patients.
Inhaled corticosteroids/LABA combination therapy improved
FEV1 by 130mL from the baseline value, which is smaller than
the results from previous studies (Mahler et al., 2002; Hanania
et al., 2003; O’Donnell et al., 2006). This difference is probably
duetothefactthatthepatientsinourstudyalreadyreceivedtreat-
ment with muscarinic receptor antagonist. In fact, the degree of
improvement in FEV1 in this study was similar to that reported
previouslywhencombinedICS/LABAwasaddedforpatientswith
COPD who had already been treated with tiotropium (Aaron
et al., 2007; Cazzola et al., 2007; Welte et al., 2009). Further-
more, ICS/LABA combination therapy improved the slope of
the single breath nitrogen washing curve which reﬂects ventila-
tion heterogeneity (Buist and Ross, 1973), but did not decrease
TLC and RV in the current study. O’Donnell et al. (2006)
have shown that ICS/LABA combination therapy improved lung
hyperinﬂation, but our data did not show reduced FRC and
RV levels. We used the helium gas dilution method to assess
the lung volume, whereas they measured the lung volume by
body plethysmography. The discrepancy in the results is pos-
sibly due to this difference in the measurement of the lung
volume.
Thereareseverallimitationsinthecurrentstudy.First,thevalue
of FENO wasrelativelyhigherthanthatof previouslyreporteddata
in patients with COPD (Dummer et al., 2009; Lehtimaki et al.,
2010). Lehtimaki et al. (2010) described that, when assessing the
role of FENO in COPD, it is important to exclude asthma since
concomitant asthma with more eosinophilic and steroid-sensitive
inﬂammationmightbiastheresults.Inthepresentstudy,although
wecarefullyexcludedpatientswithasthma,asnoneof thesubjects
hadapreviousdiagnosisorclinicalhistoryofasthma,atopicrhini-
tis,atopic dermatitis,or food allergy,we might not have been able
to completely exclude COPD patients with an asthmatic compo-
nent. Marsh et al. (2008)reported that asthma was a predominant
COPD phenotype, being present in 55% of their subjects with
COPD.Second,sincethisstudyconsistedof veryfewsubjects,fur-
ther conﬁrmation of the present results is needed in a large-scale
randomizedcontroltrial.Finally,inthepresentstudy,weanalyzed
theefﬁcacyof ICS/LABAonlyonpulmonaryfunctions.Predictive
factors for the effects on quality of life and inhibition of exacerba-
tion,whicharealsoimportantpointsof COPDpharmacotherapy,
should be studied in the future.
In summary, we have shown that the increased FENO levels
and atopy appear to be useful predictors of ICS/LABA-mediated
pulmonary function improvements in COPD.
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